[{"id":"171aed28-1c95-4308-9517-1d8f94969861","acronym":"","url":"https://clinicaltrials.gov/study/NCT00788684","created_at":"2021-01-18T02:59:25.635Z","updated_at":"2025-02-25T13:51:53.765Z","phase":"Phase 1","brief_title":"Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers","source_id_and_acronym":"NCT00788684","lead_sponsor":"AbbVie","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • navitoclax (ABT 263)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 07/21/2009","start_date":" 07/21/2009","primary_txt":" Primary completion: 02/07/2025","primary_completion_date":" 02/07/2025","study_txt":" Completion: 02/07/2025","study_completion_date":" 02/07/2025","last_update_posted":"2025-02-20"},{"id":"0829dd6e-d56c-4a78-8e9f-bd6b6b2da23c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02079740","created_at":"2021-01-18T09:35:19.928Z","updated_at":"2025-02-25T15:33:04.083Z","phase":"Phase 1/2","brief_title":"Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT02079740","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • NRAS • BCL2L2","pipe":" | ","alterations":" KRAS mutation • NRAS mutation","tags":["KRAS • NRAS • BCL2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • navitoclax (ABT 263) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 03/26/2014","start_date":" 03/26/2014","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-11"},{"id":"c84b4894-7b72-40e5-b7d9-73619eecd885","acronym":"22P.205","url":"https://clinicaltrials.gov/study/NCT05564650","created_at":"2022-10-03T15:56:48.447Z","updated_at":"2025-02-25T15:35:52.261Z","phase":"Phase 1/2","brief_title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05564650 - 22P.205","lead_sponsor":"Thomas Jefferson University","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 04/10/2026","primary_completion_date":" 04/10/2026","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2025-02-11"},{"id":"0ddf2dab-b38d-4054-a616-48669cd75157","acronym":"","url":"https://clinicaltrials.gov/study/NCT02143401","created_at":"2021-01-18T09:57:19.810Z","updated_at":"2024-07-02T16:35:01.909Z","phase":"Phase 1","brief_title":"Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT02143401","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MCL1 • AFP • CASP3","pipe":" | ","alterations":" MCL1 expression","tags":["MCL1 • AFP • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 11/07/2014","start_date":" 11/07/2014","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 05/20/2025","study_completion_date":" 05/20/2025","last_update_posted":"2024-05-22"},{"id":"cfc2985f-51c4-4ab9-8232-962b73ff7481","acronym":"NCI-2013-02103","url":"https://clinicaltrials.gov/study/NCT01989585","created_at":"2021-01-18T09:04:22.279Z","updated_at":"2024-07-02T16:35:03.325Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","source_id_and_acronym":"NCT01989585 - NCI-2013-02103","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • BCL2","pipe":" | ","alterations":" BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K","tags":["PTEN • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/24/2014","start_date":" 03/24/2014","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-16"},{"id":"a6c5fc58-82ce-40df-9b35-73d1f5f08ae5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05864742","created_at":"2023-05-18T14:05:05.741Z","updated_at":"2024-07-02T16:35:04.334Z","phase":"Phase 2","brief_title":"Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT05864742","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" BCL2 • BCL2L2 • SMARCA2","pipe":"","alterations":" ","tags":["BCL2 • BCL2L2 • SMARCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • navitoclax (ABT 263)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-05-10"},{"id":"e8364154-5f9c-4369-9f67-2f27cf14b864","acronym":"Exactis-03","url":"https://clinicaltrials.gov/study/NCT05358639","created_at":"2022-05-03T14:54:00.785Z","updated_at":"2024-07-02T16:35:43.607Z","phase":"Phase 1","brief_title":"Combination of Olaparib and Navitoclax in Women With HGSC and TNBC","source_id_and_acronym":"NCT05358639 - Exactis-03","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PALB2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • navitoclax (ABT 263)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 11/09/2022","start_date":" 11/09/2022","primary_txt":" Primary completion: 04/28/2024","primary_completion_date":" 04/28/2024","study_txt":" Completion: 04/28/2025","study_completion_date":" 04/28/2025","last_update_posted":"2023-07-07"},{"id":"7884f7af-1265-4ccd-be78-fa2be8ed7aa3","acronym":"ITALLI001","url":"https://clinicaltrials.gov/study/NCT05054465","created_at":"2021-09-23T17:53:03.625Z","updated_at":"2024-07-02T16:36:24.048Z","phase":"Phase 1b","brief_title":"A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL","source_id_and_acronym":"NCT05054465 - ITALLI001","lead_sponsor":"Israeli Medical Association","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • navitoclax (ABT 263)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2021-09-23"},{"id":"59c6f80d-6c97-43c5-b861-beaa6fc54bec","acronym":"MONAVI-1","url":"https://clinicaltrials.gov/study/NCT02591095","created_at":"2021-01-18T12:34:30.643Z","updated_at":"2024-07-02T16:37:01.571Z","phase":"Phase 2","brief_title":"A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer","source_id_and_acronym":"NCT02591095 - MONAVI-1","lead_sponsor":"Centre Francois Baclesse","biomarkers":" BCL2L11","pipe":"","alterations":" ","tags":["BCL2L11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navitoclax (ABT 263)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 04/01/2017","primary_completion_date":" 04/01/2017","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2019-03-19"},{"id":"b970ecd8-479e-4b6a-a06f-d62c63791089","acronym":"","url":"https://clinicaltrials.gov/study/NCT00445198","created_at":"2021-01-18T01:34:22.525Z","updated_at":"2024-07-02T16:37:10.250Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies","source_id_and_acronym":"NCT00445198","lead_sponsor":"AbbVie (prior sponsor, Abbott)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navitoclax (ABT 263)"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 04/01/2007","start_date":" 04/01/2007","primary_txt":" Primary completion: 12/01/2010","primary_completion_date":" 12/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2018-06-06"},{"id":"20a49b5c-d4ee-418e-8c1c-7081f35bd376","acronym":"","url":"https://clinicaltrials.gov/study/NCT01087151","created_at":"2021-01-18T04:17:14.944Z","updated_at":"2024-07-02T16:37:27.859Z","phase":"Phase 2","brief_title":"A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT01087151","lead_sponsor":"Genentech, Inc.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • navitoclax (ABT 263)"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2016-11-02"}]